FDA warned this week that several leading drugs for type 2 diabetes may cause severe and disabling joint pain. FDA said that sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain, and added a new Warning and Precaution about this risk to the labels of all dipeptidyl peptidase-4 (DPP-4) inhibitors.
Novo Nordisk is expected to find out in October whether FDA will approve its long-acting insulin Tresiba for sale in the US market. However, if approved, Tresiba faces growing competition from Sanofi, which markets the leading basal insulin Lantus along with Toujeo.
Diabetes patients taking rosiglitazone or pioglitazone had a 28 percent lower incidence of Parkinson's disease (PD) than people taking other treatments for diabetes who had never taken the glitazone (GTZ) drugs, according to a new study.
A new, painless “smart insulin patch” lowered blood glucose in a mouse model of type 1 diabetes for up to 9 hours, according to a study published in the Proceedings of the National Academy of Sciences.
Medicare beneficiaries with diabetes, high blood pressure or high cholesterol may achieve better health outcomes when using pharmacies that are part of performance-based networks, according to early results of a pay-for-performance program conducted by SCAN Health Plan and Express Scripts.
People in states that expanded Medicaid under the Affordable Care Act are far more likely to be newly identified with diabetes than in non-expansion states, according to a study published online in Diabetes Care.